Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Markers of inflammation to detect sub-optimal inhaled corticosteroid therapy in moderate-severe asthma
2006-002289-21Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Flixocort in asthma (2 arms), sponsored by Novartis. Primary endpoints: Forced expiratory volume in 1 second (FEV1) at 4 weeks and Inflammatory markers at 4 weeks. Started May 2006; status: completed.
02
Drugs
Flixocort
03
Conditions
asthma
Beyond the preview
Go deeper on 2006-002289-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002289-21.